Skip to main content

Journal of Cancer Research and Clinical Oncology

Ausgabe 8/2012

Inhalt (20 Artikel)

Review

Challenging the effectiveness of green tea in primary and tertiary cancer prevention

Hirota Fujiki, Kazue Imai, Kei Nakachi, Masahito Shimizu, Hisataka Moriwaki, Masami Suganuma

Original Paper

Overexpression and ratio disruption of ΔNp63 and TAp63 isoform equilibrium in endometrial adenocarcinoma: correlation with obesity, menopause, and grade I/II tumors

Eleni Vakonaki, Nikolaos Soulitzis, Stavros Sifakis, Danae Papadogianni, Dimitrios Koutroulakis, Demetrios A. Spandidos

Original Paper

Down-regulation of Cbl-b by bufalin results in up-regulation of DR4/DR5 and sensitization of TRAIL-induced apoptosis in breast cancer cells

Shunchao Yan, Xiujuan Qu, Chong’an Xu, Zhitu Zhu, Lingyun Zhang, Ling Xu, Na Song, Yuee Teng, Yunpeng Liu

Open Access Original Paper

Association of cytokeratin 17 expression with differentiation in oral squamous cell carcinoma

Ryoji Kitamura, Takeshi Toyoshima, Hideaki Tanaka, Shintaro Kawano, Takahiro Kiyosue, Ryota Matsubara, Yuichi Goto, Mitsuhiro Hirano, Kazunari Oobu, Seiji Nakamura

Original Paper

Estrogen is increased in male cholangiocarcinoma patients’ serum and stimulates invasion in cholangiocarcinoma cell lines in vitro

Taweewun Hunsawong, Ekapot Singsuksawat, Nuannapa In-chon, Watinee Chawengrattanachot, Chanitra Thuwajit, Banchob Sripa, Anucha Paupairoj, Siri Chau-in, Peti Thuwajit

Original Paper

The FGF2-binding peptide P7 inhibits melanoma growth in vitro and in vivo

Yonglin Yu, Susu Gao, Quchou Li, Cong Wang, Xinqiang Lai, Xilei Chen, Ruixue Wang, Jingfang Di, Tao Li, Wenhui Wang, Xiaoping Wu

Original Paper

Lentivirus-delivered ZEB-1 small interfering RNA inhibits lung adenocarcinoma cell growth in vitro and in vivo

Yi Liu, Xiaolong Yan, Na Liu, Jing Zhou, Jiayu Liu, Hailin Pang, Jian Cao, Yanfang Liu, Yanxia Wang, Lili Liu, Helong Zhang

Original Paper

The PSCA polymorphisms derived from genome-wide association study are associated with risk of gastric cancer: a meta-analysis

Danni Shi, Shizhi Wang, Dongying Gu, Dongmei Wu, Meilin Wang, Haiyan Chu, Na Tong, Lan Ma, Dongyan Zhong, Zhengdong Zhang

Original Paper

Analysis of EGF+61A>G polymorphism and EGF serum levels in Brazilian glioma patients treated with perillyl alcohol-based therapy

Francisco das Chagas Abreu da Silveira, Bruno de Almeida Lopes, Clovis Orlando da Fonseca, Thereza Quirico-Santos, Izabel Christina Nunes de Palmer Paixão, Lidia Maria da Fonte de Amorim

Original Paper

Tumor suppressor miR-22 suppresses lung cancer cell progression through post-transcriptional regulation of ErbB3

Bo Ling, Gui-Xue Wang, Guang Long, Ju-Hui Qiu, Zhong-Lei Hu

Original Paper

The link between genetic polymorphism of glutathione-S-transferases, GSTM1, and GSTT1 and diffuse large B-cell lymphoma in Egypt

Hala A. Abdel Rahman, Mervat M. Khorshied, Haidy H. Elazzamy, Ola M. Khorshid

Original Paper

FAK and Src expression in mobile tongue squamous cell carcinoma: associations with clinicopathological parameters and patients survival

Stamatios Theocharis, Jerzy Klijanienko, Constantinos Giaginis, Paraskevi Alexandrou, Efstratios Patsouris, Xavier Sastre-Garau

Original Paper

Prognostic value of nuclear matrix protein expression in localized prostate cancer

Francesco Ricci, Alessandra Rubagotti, Linda Zinoli, Rosa Mangerini, Pier Vitale Nuzzo, Giorgio Carmignani, Alchiede Simonato, Paola Barboro, Cecilia Balbi, Francesco Boccardo

Original Paper

Individual dose and scheduling determine the efficacy of combining cytotoxic anticancer agents with a kinase inhibitor in non-small-cell lung cancer

Johannes Meiler, Melanie Guyot, Sandra Hoffarth, Emmanuelle Wesarg, Yvonne Höhn, Frank Breitenbuecher, Martin Schuler

Original Paper

Chemotherapy as primary treatment for brain metastases from breast cancer: analysis of 115 one-year survivors

Willem Boogerd, Femke Groenveld, Sabine Linn, Joke W. Baars, Dieta Brandsma, Harm van Tinteren

Original Paper

Successful treatment of patients with newly diagnosed/untreated multiple myeloma and advanced renal failure using bortezomib in combination with bendamustine and prednisone

Wolfram Pönisch, Marc Andrea, Ina Wagner, Doreen Hammerschmidt, Ute Kreibich, Andreas Schwarzer, Thomas Zehrfeld, Maik Schwarz, Cornelia Winkelmann, Sirak Petros, Anette Bachmann, Tom Lindner, Dietger Niederwieser

Open Access Original Paper

A prospective multicenter study of treosulfan in elderly patients with recurrent ovarian cancer: results of a planned safety analysis

Sven Mahner, Gülten Oskay-Özcelik, Elke Heidrich-Lorsbach, Stefan Fuxius, Harald Sommer, Peter Klare, Antje Belau, Birgit Ruhmland, Thomas Heuser, Heinz Kölbl, Susanne Markmann, Jalid Sehouli

Original Paper

EGFR L861Q mutation is a frequent feature of pulmonary mucoepidermoid carcinoma

Yongfeng Yu, Zhengbo Song, Hui Gao, Lei Zhu, Shun Lu, Jie Zhang, Qingquan Luo

Rapid Communication

Low number of invariant NKT cells is associated with poor survival in acute myeloid leukemia

Alicia E. Najera Chuc, Laura A. Montiel Cervantes, Flor Pérez Retiguin, Jorge Vela Ojeda, Elba Reyes Maldonado

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.